Purified herpes simplex type 1 glycoprotein D (gD) genetically fused with the type 16 human papillomavirus E7 oncoprotein enhances antigen-specific CD8+ T Cell responses and confers protective antitumor immunity (2011)
- Authors:
- Autor USP: FERREIRA, LUIS CARLOS DE SOUZA - ICB
- Unidade: ICB
- DOI: 10.1021/mp200194s
- Assunto: MICROBIOLOGIA
- Language: Inglês
- Imprenta:
- Publisher place: Washington
- Date published: 2011
- Source:
- Título: Molecular Pharmaceutics
- ISSN: 1543-8392
- Volume/Número/Paginação/Ano: v. 8, n. 6, p. 2320-2330, 2011
- Este periódico é de acesso aberto
- Este artigo NÃO é de acesso aberto
-
ABNT
PORCHIA, Bruna Felicio Milazzotto Maldonado et al. Purified herpes simplex type 1 glycoprotein D (gD) genetically fused with the type 16 human papillomavirus E7 oncoprotein enhances antigen-specific CD8+ T Cell responses and confers protective antitumor immunity. Molecular Pharmaceutics, v. 8, n. 6, p. 2320-2330, 2011Tradução . . Disponível em: https://doi.org/10.1021/mp200194s. Acesso em: 20 fev. 2026. -
APA
Porchia, B. F. M. M., Diniz, M. O., Cariri, F. A. M. O., Santana, V. C., Amorim, J. H., Balan, A., et al. (2011). Purified herpes simplex type 1 glycoprotein D (gD) genetically fused with the type 16 human papillomavirus E7 oncoprotein enhances antigen-specific CD8+ T Cell responses and confers protective antitumor immunity. Molecular Pharmaceutics, 8( 6), 2320-2330. doi:10.1021/mp200194s -
NLM
Porchia BFMM, Diniz MO, Cariri FAMO, Santana VC, Amorim JH, Balan A, Braga CJM, Ferreira LC de S. Purified herpes simplex type 1 glycoprotein D (gD) genetically fused with the type 16 human papillomavirus E7 oncoprotein enhances antigen-specific CD8+ T Cell responses and confers protective antitumor immunity [Internet]. Molecular Pharmaceutics. 2011 ; 8( 6): 2320-2330.[citado 2026 fev. 20 ] Available from: https://doi.org/10.1021/mp200194s -
Vancouver
Porchia BFMM, Diniz MO, Cariri FAMO, Santana VC, Amorim JH, Balan A, Braga CJM, Ferreira LC de S. Purified herpes simplex type 1 glycoprotein D (gD) genetically fused with the type 16 human papillomavirus E7 oncoprotein enhances antigen-specific CD8+ T Cell responses and confers protective antitumor immunity [Internet]. Molecular Pharmaceutics. 2011 ; 8( 6): 2320-2330.[citado 2026 fev. 20 ] Available from: https://doi.org/10.1021/mp200194s - Evaluation of experimental conditions for quantification of LT produced by human derived enterotoxigenic Escherichia coli strains
- New vaccine approaches against enteropathogenic and enteroheamorrhagic Escherichia coli strains based on intimin expression by recombinant Bacillus subtilis strains
- New vaccine approaches against enteropathogenic and enteroheamorrhagic Escherichia coli strains
- Gene delivery and immunomodulatory effects of plasmid DNA associated with Branched Amphiphilic Peptide Capsules
- Bacillus subtilis spores as vaccine adjuvants: further insights into the mechanisms of action
- Protection against HPV-16-associated tumors requires the activation of CD8+ effector memory T cells and the control of myeloid-derived suppressor cells
- Enhanced therapeutic effects conferred by an experimental DNA vaccine targeting human papillomavirus-induced tumors
- Bivalent DNA vaccines confer prophylactic and therapeutic effect on HPV-16 murine tumor
- Expression of a treptococcal M protein epitope fused at different sites of flagellin (FliCd) as an approach for the development of bivalent vaccines based on attenuated Salmonella strains
- Evaluation of the prophylactic and therapeutic effects of anti-cancer DNA vaccine encoding the HPV-16 E7 oncoprotein genetically fused to the HSV-1 GD
Informações sobre o DOI: 10.1021/mp200194s (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
